FDA
-
-
-
-
-
-
-
Carisma Therapeutics (CARM) and Moderna Expand Collaboration to Develop Two In Vivo CAR-M Therapies for Autoimmune Diseases
-
-
-
-
-
-
-
Carisma Therapeutics Granted FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid Tumors
-
-
-
-
-
-
-
Carisma Therapeutics (CARM) Reports Q4, Provides Business Update
-
-
-
-
-
-
-
Carisma Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights
-
322,096 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

